CCR9抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08113(CCR9 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08113(CCR9 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

CCR9 is a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, primarily expressed on immune cells, particularly T lymphocytes. It interacts with its sole ligand, CCL25 (TECK), which is predominantly secreted in the thymus and gastrointestinal tract. This receptor-ligand pair plays a critical role in directing immune cell migration to mucosal tissues, especially the small intestine, making CCR9 a key mediator in gut-specific immune responses and inflammation. Dysregulation of the CCR9/CCL25 axis has been implicated in inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, where excessive T-cell infiltration contributes to chronic tissue damage.

CCR9-targeting antibodies are designed to block this interaction, thereby inhibiting pathological immune cell trafficking. Early research focused on developing monoclonal antibodies (mAbs) or small-molecule antagonists to neutralize CCR9. Preclinical studies demonstrated reduced inflammation in IBD models, supporting its therapeutic potential. However, clinical trials have shown mixed outcomes, partly due to CCR9's complex role in immune homeostasis and redundancy in chemokine signaling. Beyond IBD, CCR9 is explored in oncology, as certain cancers (e.g., melanoma, leukemia) exploit this receptor for metastasis or immune evasion. Current efforts aim to refine antibody specificity and evaluate combination therapies to enhance efficacy while minimizing systemic immunosuppression.